Phospholipase A2 (PLA2) is a superfamily of enzymes that cleave the sn-2 ester bond of membrane phospholipids, liberating arachidonic acid and lysophospholipids. This enzymatic action initiates the eicosanoid synthesis cascade, serving as the rate-limiting step in producing both pro-inflammatory and pro-resolving lipid mediators. PLA2 activity thus functions as the critical gateway between membrane fatty acid composition and systemic inflammatory tone.
Think of your cell membrane as a neighbourhood where fatty acids are parked cars in driveways. PLA2 is the tow truck operator who selectively removes specific cars (fatty acids) from their parking spots (phospholipid scaffolds). If the neighbourhood is dominated by omega-6 cars (linoleic acid, arachidonic acid), the tow truck mostly delivers inflammatory vehicles to the body shop downstream—these get converted into pro-inflammatory Prostaglandins, leukotrienes, and pain-signaling oxylipins. If the neighbourhood has more omega-3 cars (EPA, DHA), the tow truck delivers anti-inflammatory materials instead. The tow truck doesn't care which car it picks up—it just follows demand signals (inflammation, injury, Calcium spikes). But the type of car it delivers determines whether you get a street fight (chronic inflammation) or a peace treaty (specialized pro-resolving mediators). The PLA2G7 variant is like a specialized tow truck that specifically picks up oxidized, damaged cars and delivers them to pain receptors (TRPV1), causing nerve sensitization and peripheral neuropathy.
The PLA2 superfamily comprises multiple isoforms with distinct regulatory mechanisms and tissue distributions:
cPLA2 (cytosolic PLA2, Group IV):
sPLA2 (secretory PLA2, Groups IIA, V, X):
- Secreted into extracellular space during inflammation
- Requires millimolar Calcium concentrations (10-100× higher than cPLA2)
- Found in high concentrations in synovial fluid (rheumatoid arthritis), pancreatic secretions, venom
- Less substrate-specific than cPLA2; cleaves multiple phospholipid species
- sPLA2-IIA elevated in acute phase response (can reach >100 ng/mL in sepsis)
- Functions as acute phase protein and antimicrobial agent (disrupts bacterial membranes)
iPLA2 (calcium-independent PLA2, Group VI):
- Active without Calcium requirement
- Involved in membrane phospholipid remodeling and homeostatic functions
- Regulated by ATP binding and Calmodulin inhibition
- Preferentially releases polyunsaturated fatty acids for membrane repair
PLA2G7 (lipoprotein-associated PLA2/Lp-PLA2):
- Binds to LDL and HDL particles in circulation
- Specifically hydrolyzes oxidized phospholipids → generates oxylipins (9-HODE, 13-HODE, 12,13-diHOME)
- These oxylipins (especially 12,13-diHOME) activate TRPV1 channels on dorsal root ganglia sensory neurons
- Chronic activation → ATF3 expression in sensory neurons → small fiber neuropathy
- High dietary linoleic acid → increased neuronal membrane LA content → more PLA2G7 substrate → pronociceptive oxylipin accumulation
graph TD
A["Inflammatory Stimulus<br/>TNF-α, IL-1β, Calcium"] --> B["cPLA2 Activation<br/>ERK1/2 → Ser505 phosphorylation"]
B --> C["Membrane Phospholipid Cleavage<br/>sn-2 position"]
C --> D[Arachidonic Acid Release]
C --> E[Lysophospholipid Production]
D --> F[COX-2 Pathway]
D --> G[5-LOX Pathway]
D --> H[15-LOX Pathway]
F --> I["PGE2, PGI2, TXA2<br/>Pro-inflammatory prostaglandins"]
G --> J["LTB4, Cysteinyl LTs<br/>Pro-inflammatory leukotrienes"]
H --> K["Lipoxins, Resolvins<br/>Pro-resolving mediators"]
L[High Omega-6 Diet] --> M["Membrane Enrichment<br/>LA, AA in phospholipids"]
M --> N[PLA2G7 Activation]
N --> O["Oxylipin Generation<br/>9-HODE, 13-HODE, 12,13-diHOME"]
O --> P["TRPV1 Activation<br/>Dorsal root ganglia"]
P --> Q["ATF3 Expression<br/>Neuropathic pain markers"]
Q --> R["IENF Density Loss<br/>Small fiber neuropathy"]
Post-translational regulation:
- S-nitrosylation of cPLA2 by Nitric Oxide → reduced activity (feedback inhibition)
- Annexin A1 directly inhibits PLA2 activity (mechanism underlying glucocorticoid anti-inflammatory effects)
- Lipocortin-1 (annexin A1) expression induced by Cortisol → PLA2 inhibition → reduced eicosanoid synthesis
Substrate availability determines product profile:
Central role in inflammatory control:
PLA2 represents the first committed step in eicosanoid biosynthesis, making it the primary control point for inflammatory lipid mediator production. Unlike COX-2 inhibition (which only blocks prostaglandin synthesis), PLA2 activity governs the entire cascade including leukotrienes, lipoxins, and specialized pro-resolving mediators. This explains why dietary fatty acid balance affects inflammation even in patients taking NSAIDs.
Diet-induced neuropathy mechanism (Metamodel 5 - Mismatch):
The modern Western diet's omega-6 dominance (ratio often 20:1 instead of ancestral 1-4:1) creates membrane phospholipids enriched with linoleic acid and arachidonic acid. Chronic low-grade activation of PLA2G7 in this context generates a persistent stream of pronociceptive oxylipins that activate TRPV1 channels on sensory neurons. This mechanism underpins diet-induced neuropathy independent of hyperglycemia or traditional neuropathy risk factors. Patients present with burning feet, peripheral neuropathy, and reduced IENF density despite normal glucose metabolism.
Clinical thresholds and biomarkers:
- sPLA2-IIA >10 ng/mL indicates systemic inflammation (sepsis, severe trauma)
- PLA2G7 activity >200 nmol/min/mL associated with increased cardiovascular risk
- Elevated PLA2G7 + high omega-6:omega-3 ratio (>10:1) = neuropathy risk profile
- IENF density <5 fibers/mm at ankle indicates small fiber neuropathy (PLA2-mediated nerve damage)
Therapeutic implications:
- darapladib (selective PLA2G7 inhibitor) tested in neuropathy trials—showed IENF density preservation but limited pain relief (suggests structural vs. functional dissociation)
- Dietary intervention: reducing linoleic acid to <5% energy + increasing EPA/DHA (2-4g/day) → reduced membrane substrate → decreased pronociceptive oxylipin production
- Anti-inflammatory diet effectiveness depends on membrane remodeling time (3-6 months for neuronal phospholipid turnover)
- Curcumin and ginger compounds inhibit PLA2 activity (mechanism underlying anti-inflammatory effects)
Metamodel integration:
- Selfish Immune System: PLA2 activation prioritizes acute inflammatory defense even at cost of chronic tissue damage (pain as acceptable trade-off for pathogen control)
- Metamodel 0 (Location): PLA2 isoforms show tissue-specific distribution—sPLA2 in inflammatory fluids, cPLA2 in neurons and immune cells, PLA2G7 in circulation bound to lipoproteins
- Metamodel 4 (Gut-Brain-Immune): Gut barrier dysfunction → LPS translocation → cPLA2 activation → neuroinflammation cascade
Patient populations:
- Fibromyalgia patients often show elevated PLA2 activity with high-sensitivity pain phenotype
- Chronic pain syndromes with high omega-6 intake show better response to dietary omega-3 supplementation
- Rheumatoid arthritis patients have 10-100× elevated synovial fluid sPLA2 (treatment target)
- Inflammatory bowel disease patients show intestinal PLA2 upregulation (mucosal damage amplifier)
- Three main PLA2 families: cytosolic (cPLA2, Ca²⁺-dependent), secretory (sPLA2, high Ca²⁺ requirement), calcium-independent (iPLA2)
- cPLA2 activation threshold: requires ~1 μM intracellular Calcium plus ERK1-2 phosphorylation at Ser505
- Substrate specificity: cPLA2 preferentially releases arachidonic acid; sPLA2 less selective; PLA2G7 targets oxidized phospholipids
- Product dual function: releases both arachidonic acid (eicosanoid precursor) and lysophospholipids (signaling molecules, membrane remodeling)
- PLA2G7 produces pronociceptive oxylipins: 12,13-diHOME activates TRPV1 channels on sensory neurons at nanomolar concentrations
- Rate-limiting enzyme: PLA2 activity controls eicosanoid production more than downstream COX or LOX enzymes
- Membrane composition determines output: omega-6-rich membranes → pro-inflammatory products; omega-3-rich → pro-resolving mediators
- sPLA2-IIA is acute phase protein: increases 10-1000× during acute inflammation (normal <10 ng/mL, sepsis >100 ng/mL)
- Glucocorticoid mechanism: Cortisol induces Annexin A1 → direct PLA2 inhibition (major anti-inflammatory pathway)
- Neuronal membrane remodeling: 3-6 months required to change neuronal phospholipid fatty acid composition via diet
- IENF loss threshold: <5 fibers/mm at ankle indicates PLA2-mediated small fiber neuropathy
- Darapladib effects: PLA2G7 inhibitor preserves nerve fiber density but doesn't reverse established pain (structure ≠ function)
- arachidonic acid — primary fatty acid released from membrane phospholipids by PLA2; substrate for COX, LOX, CYP450 pathways
- linoleic acid — dietary omega-6 that accumulates in neuronal and immune cell membranes, increasing pro-inflammatory PLA2 substrate pool
- PLA2G7 — specific PLA2 isoform that generates pronociceptive oxylipins from oxidized omega-6 fatty acids in circulation
- eicosanoids — collective term for PLA2-derived lipid mediators including prostaglandins, leukotrienes, lipoxins
- COX-2 — uses PLA2-released arachidonic acid to synthesize PGE2 and other prostaglandins
- 5-LOX — converts PLA2-released AA into Leukotriene B4 and cysteinyl leukotrienes
- 15-LOX — generates lipoxins and specialized pro-resolving mediators from PLA2-released omega-3 and omega-6 substrates
- PGE2 — major pro-inflammatory prostaglandin synthesized from PLA2-released AA via COX-2 pathway
- Leukotriene B4 — potent neutrophil chemoattractant produced from PLA2-derived AA via 5-LOX
- oxylipins — oxidized fatty acid metabolites generated by PLA2G7 that activate pain receptors
- TRPV1 — capsaicin/heat receptor on nociceptors activated by PLA2G7-derived oxylipins (12,13-diHOME)
- peripheral neuropathy — caused by chronic exposure to PLA2-generated pronociceptive lipid mediators
- dorsal root ganglia — sensory neuron cell bodies where PLA2-derived oxylipins induce ATF3 expression and nerve damage
- lysophospholipids — second product of PLA2 activity with diverse signaling functions; some are pro-inflammatory, others pro-resolving
- darapladib — selective PLA2G7 inhibitor tested for neuropathy treatment; preserves IENF density but limited analgesic effect
- omega-6 to omega-3 ratio — high ratio (>10:1) increases pro-inflammatory vs. pro-resolving PLA2 product balance
- chronic pain — sustained PLA2 activity generates continuous pronociceptive mediator production, especially in high omega-6 states
- inflammation — PLA2 is the gateway enzyme controlling entire inflammatory lipid mediator cascade
- diet-induced neuropathy — high omega-6 diet provides excess substrate for PLA2-mediated oxylipin generation and nerve sensitization
- neuropathic pain — PLA2-generated oxylipins chronically activate and sensitize pain pathways independent of tissue injury
- membrane phospholipids — storage depot for fatty acid substrates; composition determines PLA2 product profile
- Calcium — required cofactor for cPLA2 activation; inflammatory signals raise intracellular Ca²⁺ to activate enzyme
- EPA — omega-3 fatty acid that competes with AA for PLA2 cleavage; generates anti-inflammatory/pro-resolving mediators
- DHA — omega-3 fatty acid in neuronal membranes; PLA2 release generates neuroprotective resolvins and protectins
- specialized pro-resolving mediators — resolvins, protectins, maresins generated from PLA2-released omega-3 fatty acids
- IENF density — intraepidermal nerve fiber density reduced by chronic PLA2-mediated oxylipin exposure; biomarker for small fiber neuropathy
- ATF3 — activating transcription factor 3; stress marker expressed in sensory neurons exposed to PLA2-derived neurotoxic oxylipins
- small fiber neuropathy — loss of unmyelinated C-fibers and thinly myelinated A-delta fibers due to PLA2-mediated oxylipin toxicity
- Annexin A1 — glucocorticoid-induced protein that directly inhibits PLA2 activity; mediates anti-inflammatory effects of cortisol
- Cortisol — induces annexin A1 expression → PLA2 inhibition → reduced eicosanoid synthesis (major anti-inflammatory mechanism)
- TNF-α — pro-inflammatory cytokine that activates cPLA2 via ERK1/2 pathway, amplifying inflammatory lipid mediator production
- IL-1β — activates cPLA2 through MAPK signaling; creates positive feedback loop for inflammation
- ERK1-2 — MAP kinase that phosphorylates cPLA2 at Ser505, enabling enzyme activation and AA release
- Nitric Oxide — S-nitrosylates cPLA2 causing feedback inhibition; limits excessive inflammatory lipid mediator production
- Curcumin — natural PLA2 inhibitor; mechanism underlying turmeric's anti-inflammatory effects
- ginger — contains gingerols that inhibit PLA2 activity; traditional anti-inflammatory application
- Fibromyalgia — condition associated with elevated PLA2 activity and high-sensitivity pain phenotype
- rheumatoid arthritis — synovial fluid sPLA2 levels 10-100× normal; therapeutic target for disease modification
- inflammatory bowel disease — intestinal PLA2 upregulation contributes to mucosal barrier damage and inflammation amplification